http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4023232-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2694fd4c63bfaa7635c0c1ff05d8af5
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24021
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-07
filingDate 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434bc6196fa8b6da09d9c44cf9a98743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ca10a4c508f18831eb63712f6ff688
publicationDate 2022-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-4023232-A4
titleOfInvention PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER WITH ANTI-CANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS
priorityDate 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018195552-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011003194-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010135242-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3657
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559251

Total number of triples: 38.